Literature DB >> 23850493

Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.

Xiaoxiang Chen1, Jing Zhang, Zhihong Zhang, Hongxia Li, Wenjun Cheng, Jinsong Liu.   

Abstract

Although epithelial ovarian cancer cells are eliminated by debulking surgery and chemotherapy during initial treatment, it is believed that only a subset of cancer cells, that is, cancer stem cells, may be an important source of tumor recurrence and drug resistance. This review highlights our current understanding of high-grade serous carcinoma, ovarian cancer stem cells, common methods for enrichment of ovarian cancer stem cells, mechanisms involved in drug resistance, and potential strategies for overcoming drug resistance, with associated potential controversies and pitfalls. We also review the potential relationship between epithelial-to-mesenchymal transition and cancer stem cells and how we can induce cancer cells to differentiate into benign stromal fibroblasts in response to certain chemotherapy drugs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cell; Epithelial-mesenchymal transition; High-grade ovarian serous cancer

Mesh：

Substances：

Year:  2013        PMID： 23850493      PMCID： PMC3797876          DOI： 10.1016/j.humpath.2013.05.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN： 0046-8177            Impact factor:   3.466


  127 in total

Review 1.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

2.  Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

Authors:  Debra A Bell; Teri A Longacre; Jaime Prat; Elise C Kohn; Robert A Soslow; Lora H Ellenson; Anais Malpica; Mark H Stoler; Robert J Kurman
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

3.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

4.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

5.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

6.  Stem-like ovarian cancer cells can serve as tumor vascular progenitors.

Authors:  Ayesha B Alvero; Han-Hsuan Fu; Jennie Holmberg; Irene Visintin; Liora Mor; Carlos Cano Marquina; Jessica Oidtman; Dan-Arin Silasi; Gil Mor
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

7.  Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Authors:  Mark Shackleton; Elsa Quintana; Eric R Fearon; Sean J Morrison
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

8.  Purification and characterization of mouse hematopoietic stem cells.

Authors:  G J Spangrude; S Heimfeld; I L Weissman
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

9.  Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973.

Authors:  E Björkholm; F Pettersson; N Einhorn; I Krebs; B Nilsson; B Tjernberg
Journal:  Acta Radiol Oncol       Date:  1982

10.  Clinical significance of side population in ovarian cancer cells.

Authors:  Shinji Hosonuma; Yoichi Kobayashi; Satoshi Kojo; Haruka Wada; Ken-ichiro Seino; Kazushige Kiguchi; Bunpei Ishizuka
Journal:  Hum Cell       Date:  2011-01-07       Impact factor: 4.174
View more
  26 in total

1.  Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.

Authors:  Kun Zhang; Haixing Song; Ping Yang; Xiaozhen Dai; Ya Li; Lan Wang; Jun Du; Kejian Pan; Tao Zhang
Journal:  Cell Prolif       Date:  2015-01-21       Impact factor: 6.831

2.  Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

Authors:  Nicholas W Bateman; Elizabeth Jaworski; Wei Ao; Guisong Wang; Tracy Litzi; Elizabeth Dubil; Charlotte Marcus; Kelly A Conrads; Pang-ning Teng; Brian L Hood; Neil T Phippen; Lisa A Vasicek; William P McGuire; Keren Paz; David Sidransky; Chad A Hamilton; G Larry Maxwell; Kathleen M Darcy; Thomas P Conrads
Journal:  J Proteome Res       Date:  2015-03-19       Impact factor: 4.466

Review 3.  Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.

Authors:  Mohammad Aslam Khan; Kunwar Somesh Vikramdeo; Sarabjeet Kour Sudan; Seema Singh; Annelise Wilhite; Santanu Dasgupta; Rodney Paul Rocconi; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2021-08-18       Impact factor: 15.707

4.  A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.

Authors:  Curtis W McCloskey; Reuben L Goldberg; Lauren E Carter; Lisa F Gamwell; Ensaf M Al-Hujaily; Olga Collins; Elizabeth A Macdonald; Kenneth Garson; Manijeh Daneshmand; Euridice Carmona; Barbara C Vanderhyden
Journal:  Front Oncol       Date:  2014-03-18       Impact factor: 6.244

5.  Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.

Authors:  Xia Xu; Fei Deng; Mengmeng Lv; Binhui Ren; Wenwen Guo; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2016-12-02       Impact factor: 4.234

6.  The significance of the alteration of 8-OHdG in serous ovarian carcinoma.

Authors:  Xia Xu; Yan Wang; Wenwen Guo; Yiqing Zhou; Chunmei Lv; Xiaoxiang Chen; Kaijiang Liu
Journal:  J Ovarian Res       Date:  2013-10-29       Impact factor: 4.234

7.  RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.

Authors:  Yuting Huang; Meng Zhao; Haixu Xu; Ke Wang; Zheng Fu; Yuan Jiang; Zhi Yao
Journal:  Oncotarget       Date:  2014-08-30

8.  Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.

Authors:  Irma Virant-Klun; Natasa Kenda-Suster; Spela Smrkolj
Journal:  J Ovarian Res       Date:  2016-03-03       Impact factor: 4.234

Review 9.  Prostate Cancer Stem Cells: Research Advances.

Authors:  Dagmara Jaworska; Wojciech Król; Ewelina Szliszka
Journal:  Int J Mol Sci       Date:  2015-11-17       Impact factor: 5.923

10.  Gigantol Inhibits Epithelial to Mesenchymal Process in Human Lung Cancer Cells.

Authors:  Thitita Unahabhokha; Pithi Chanvorachote; Boonchoo Sritularak; Jutarat Kitsongsermthon; Varisa Pongrakhananon
Journal:  Evid Based Complement Alternat Med       Date:  2016-08-29       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.